SCHEMBL4251318

SCHEMBL4251318

COC(=O)c1nn2ccc(C(=O)O)nc2c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.38
▸ KDM4E B2RXH2 9/20 0.38
▸ L3MBTL1 Q9Y468 4/20 0.38
▸ ALDH1A1 P00352 6/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ F2 P00734 1/20 0.35
▸ PLAU P00749 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ AKT2 P31751 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251315 0.92 NPSR1 (0.39) GAAKDM4EL3MBTL1ALDH1A1KMT2A
SCHEMBL21001663 0.70 KDM4E (0.45) GAAKDM4EL3MBTL1ALDH1A1KMT2A
SCHEMBL28569322 0.69 KDM4E (0.53) KDM4EL3MBTL1ALDH1A1KMT2AMAPK1
SCHEMBL13500701 0.67 SCN5A (0.42) KDM4EL3MBTL1ALDH1A1MAPTRAB9A
SCHEMBL9107846 0.67 DHODH (0.52) GAAKDM4EL3MBTL1ALDH1A1POLB
SCHEMBL31432467 0.65 KDM4E (0.47) GAAKDM4EL3MBTL1ALDH1A1MAPK1
SCHEMBL21014290 0.65 KDM4E (0.42) GAAKDM4EL3MBTL1ALDH1A1KMT2A
SCHEMBL17141136 0.64 KDM4E (0.43) GAAKDM4EL3MBTL1ALDH1A1KMT2A
SCHEMBL20610153 0.64 NPSR1 (0.44) KDM4EL3MBTL1ALDH1A1KMT2AMAPK1
SCHEMBL15231246 0.64 KDM4E (0.42) GAAKDM4EL3MBTL1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102211-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS Alantos Pharmaceuticals Holding, Inc. (US) 2009-09-23 — — EP disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 — — US disclosed
WO-2008063671-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 — — WO disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ADAMTS4, ADAMTS1, ADAMTS5 GAA 504/4885KDM4E 418/4885L3MBTL1 4494/4885
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors ADAM17, ADAM8, ADAM10 GAA 150/4885KDM4E 2588/4885L3MBTL1 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback